Alzheimer's Pioneer Hardy Outlines Path Beyond Amyloid-Clearing Drugs

Sir John Hardy, the University College London neuroscientist whose 1990s research established the central role of amyloid protein in Alzheimer's disease, told attendees at the WIRED Health event that recent drug approvals represent only the beginning of effective dementia treatment, not its endpoint.

Hardy's foundational amyloid research directly enabled the development of donanemab and lecanemab, the first FDA-approved therapies capable of removing amyloid deposits from the brain. Both drugs received regulatory approval in 2024 — lecanemab in January and donanemab (branded as Kisunla) in July — marking the first disease-modifying treatments to reach market after decades of failed attempts targeting the amyloid pathway.

The clinical results from both therapies validate Hardy's core hypothesis while exposing its limitations. Lecanemab trials demonstrated the drug could slow cognitive decline but failed to halt Alzheimer's progression entirely. Donanemab showed similar efficacy in late-stage trials, reducing memory and thinking decline by 29% compared to placebo controls, yet patients continued to deteriorate.

Infrastructure Gaps Block Treatment Access

Hardy emphasized that pharmaceutical breakthroughs alone cannot address the scale of the dementia crisis without corresponding investments in diagnostic infrastructure and care delivery systems. Current diagnostic accuracy rates remain problematic, with many Alzheimer's patients receiving incorrect diagnoses according to Hardy's assessment at the WIRED Health presentation.

The diagnostic bottleneck compounds broader systemic challenges in translating research advances into patient outcomes. Only about 12,000 Alzheimer's patients enroll in clinical trials annually, falling well short of the 50,000-plus participants needed to fully staff the 182 trials in the current pipeline. This participation gap exists despite polling data indicating most American adults express interest in joining Alzheimer's trials.

Clinical trial capacity constraints limit the development timeline for promising candidates including ALZ-801, positioned as the first oral disease-modifying Alzheimer's therapy. The drug's manufacturer plans to submit its FDA application in 2024, potentially offering patients an alternative to the intravenous administration required for current amyloid-clearing treatments.

Side Effect Profiles Constrain Deployment

Both approved amyloid-targeting drugs carry significant safety considerations that limit their clinical deployment. Donanemab causes amyloid-related imaging abnormalities (ARIA) including brain edema, effusions, and hemorrhage deposits. These side effects require regular MRI monitoring throughout treatment, adding complexity and cost to patient management protocols.

The ARIA risk profile effectively narrows the eligible patient population to those with mild cognitive impairment or early-stage dementia, excluding advanced patients who might benefit from amyloid reduction but cannot tolerate the monitoring requirements or inflammatory responses.

Worth flagging: the regulatory approval timeline for these drugs occurred remarkably quickly by historical standards, with the FDA's Peripheral and Central Nervous System Drugs Advisory Committee reviewing donanemab data in June 2024 and granting approval within weeks. This accelerated review process reflects both the unmet medical need and the strength of the efficacy data, but also places additional emphasis on post-market surveillance to identify any long-term safety signals.

Pipeline Expansion Beyond Amyloid

The 2024 Alzheimer's drug development pipeline encompasses 171 ongoing studies testing 134 distinct therapeutic candidates, representing the most robust research effort in the field's history. This expansion reflects both increased confidence in druggable targets and substantial venture funding flowing into neurodegenerative disease research over the past five years.

Several pipeline candidates target mechanisms beyond amyloid clearance, including tau protein aggregation, neuroinflammation, and synaptic preservation. The diversification acknowledges that amyloid removal, while necessary, may be insufficient for comprehensive disease modification in many patients.

International market expansion is proceeding in parallel with pipeline development. Eisai's Leqembi secured Chinese regulatory approval in January 2024, followed by Eli Lilly's Kisunla approval in December. These approvals establish precedent for global deployment while generating real-world evidence on efficacy across diverse patient populations.

Historical Pattern Recognition

The current state of Alzheimer's therapeutics resembles the early days of HIV treatment in the mid-1990s, when the first protease inhibitors demonstrated clear antiviral activity but required combination with other mechanisms to achieve sustained viral suppression. The parallel extends to the initial focus on single-target approaches before the field recognized that complex diseases require multi-modal intervention strategies.

Hardy's research trajectory from genetic discovery to therapeutic validation spans three decades, illustrating the extended timeline required for translating basic neuroscience findings into clinical applications. His identification of mutations in the amyloid precursor protein (APP) gene at UCL provided the mechanistic foundation for today's antibody-based therapies, but the path from target identification to approved drugs required multiple technological advances in protein engineering, biomarker development, and clinical trial design.

Integration Requirements

Looking at what this means for healthcare systems, the integration of amyloid-clearing therapies requires substantial infrastructure investments beyond drug procurement costs. Treatment protocols demand specialized imaging capabilities, neurologist capacity, and infusion center access — resources that remain unevenly distributed across healthcare networks.

Hardy's call for enhanced political will reflects the reality that effective dementia treatment will require coordinated policy responses addressing diagnostic standards, care coordination, and research funding allocation. The current therapeutic toolkit provides proof-of-concept for disease modification while exposing the complexity of implementing precision medicine approaches in neurodegenerative disorders.

The emergence of combination approaches, exemplified by Karuna's successful pairing of an Eli Lilly Alzheimer's candidate with complementary mechanisms for schizophrenia treatment, suggests that the field is evolving toward multi-target strategies that address the full spectrum of neurological dysfunction in dementia.

Hardy's recognition alongside only two other scientists on Esquire's 2025 Better Men List acknowledges his role in establishing the scientific foundation for current therapeutic advances while highlighting the distance remaining between initial breakthroughs and comprehensive treatment solutions. The trajectory from genetic discovery to clinical application continues, with the next phase focused on optimizing delivery, expanding access, and developing combination therapies that can halt disease progression rather than merely slowing its advance.